The Business Cocktail

The Business Cocktail

Aug 02, 2016

  • Juno Therapeutics recently acquired Redox Therapies and it’s vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist. The upfront consideration for the Redox Therapies acquisition was $10 million in cash.
  • UK-based Cell Medica expands its T cell immunotherapy program with the acquisition of privately-held Delenex Therapeutics
  • Evelo Biosciences, US based Microbiome Company working in oncology through characterization of cancer associated bacteria, and Epiva Biosciences, another microbiome company from Flagship VentureLabs, merged to create a leading immuno-microbiome platform company in the U.S.
  • Medivation Inc., an American biopharmaceutical company working for the development of novel therapeutics, enters confidentiality agreement with French Drugmaker, Sanofi, who agreed to terminate its consent solicitation.
  • AstraZeneca is considering $10 billion bid for Medivation Inc., an American biopharmaceutical company, according to reports, however no formal offers have been made.
  • Evelo Biosciences, a pioneer in Oncobiotics, and Mayo Clinic, U.S.A. entered into an exclusive research collaboration for Immuno-microbiome Cancer Therapies, for advance development of cancer-associated bacteria library, a key platform discovery tool of the former for the development of onco-microbials to treat cancer.

Downloads

Article in PDF

Recent Articles
metastatic-colorectal-cancer-drugs-in-development
Articles

Dec 01, 2025

The Next Wave of Metastatic Colorectal Cancer Drug Treatment: 6 Therapies Poised to Change the Landscape

redemplo-for-fcs
Articles

Nov 28, 2025

Arrowhead Hits the Mark in FCS Treatment with REDEMPLO Approval—Now Comes the Ionis Challenge

pharma-news-for-novartis-bayer-novo
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Nov 25, 2025

Novartis Secures FDA Approval for ITVISMA; Kelun-Biotech’s Phase III Study Shows Sac-TMT + Keytruda Achieves Primary Endpoint in First-Line PD-L1-Positive NSCLC; Evoke Phase 3 Trials Failed to Show a Statistically Significant Impact on Alzheimer’s Disease Progression; Sangamo Therapeutics Gets FDA Nod for Rolling BLA Submission of ST-920 in Fabry Disease; Bayer’s HYRNUO Receives FDA Accelerated Approval for Previously Treated HER2-mutant NSCLC

loader
loader